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RESEARCH NOTE
The challenges of muscle biopsy 
in a community based geriatric population
Daisy Wilson* , Leigh Breen, Janet M. Lord and Elizabeth Sapey
Abstract 
Objectives: To describe the difficulties of obtaining muscle samples using a Bergstrom needle technique in a frail 
older adult population. The data were obtained from a study primarily investigating immunosenescence in frailty. An 
intended research technique was skeletal muscle biopsy in a small subset of participants to investigate muscle mor-
phology and local inflammatory factors.
Results: Forty healthy older adults and 37 frail older adults were considered for a Bergstrom needle muscle biopsy. 
Of these, 17.5% of healthy older adults and 94.6% of the frail older adults had single or multiple participant factors 
resulting in a contra-indication to muscle biopsy. 40.7% of healthy older female participants were at risk of a failed 
muscle biopsy due to low muscle mass. Considering only muscle mass muscle biopsy would have been successful 
in 18.7% of the frail older women and 21.4% of the frail older men. In this population, muscle biopsy was not feasible 
because of contra-indications in the majority of participants. This questions whether a biopsy sample obtained from 
frail older individuals, is actually representative of this population and supports the need to disclose biopsy failure rate 
in this population.
Keywords: Sarcopenia, Frailty, Bergstrom needle, Percutaneous muscle biopsy
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Introduction
Sarcopenia, the loss of muscle mass and physical func-
tion, and frailty, a syndrome of diminished strength, 
endurance, and reduced physiological function that 
increases the risk of adverse outcomes, are both common 
conditions affecting older adults [1, 2]. The syndromes 
although separate conditions share several characteristics 
and often co-exist in the same individual, the relation-
ship between the two conditions is complex and poorly 
defined [3]; these reviews address these aspects in greater 
detail [4, 5]. The pathophysiology of both syndromes is 
complex, however, reduced muscle health is central to 
both conditions [6]. ‘Muscle quality’, including morpho-
logical characteristics of the muscle, aerobic capacity, 
intramuscular adipose tissue, fibrous tissue and motor 
units [7], is considered to be as, or more, important than 
muscle mass in the development of sarcopenia and frailty.
Investigators require muscle tissue to investigate fac-
tors contributing to muscle quality. Although animal 
models exist, the ability of these models to recapitulate 
the complexity and heterogeneity of both syndromes is 
limited [8], necessitating the use of human tissue. Muscle 
tissue from humans can be obtained from either a percu-
taneous muscle biopsy, preferred for most research, or as 
a by-product of surgery, where the sample may be altered 
by the surgery itself rather than the underlying condition. 
Percutaneous muscle biopsy has been used with success 
on multiple occasions in individuals with sarcopenia [9–
12] and on fewer occasions in frailty [13]. A recent study 
reported on both the acceptability and feasibility of mus-
cle biopsy in an older community-dwelling male popula-
tion and highlighted the importance of completing this 
procedure in a frail population [11]. Ultrasound guid-
ance for the prior assessment of muscle thickness and 
site choice is not mandated for muscle biopsy [14], but is 
becoming increasingly popular with researchers [15, 16].
This paper reports on the difficulties of obtaining mus-
cle samples using a percutaneous Bergstrom needle tech-
nique in a frail older adult population [14] and potential 
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problems in obtaining reasonable muscle sample sizes 
in both healthy older adults and frail older adults. The 
data were obtained from a study primarily investigating 
immunosenescence in frailty. An intended research tech-
nique was muscle biopsy in a small subset of participants 
(N = 5) to obtain muscle samples to investigate muscle 
morphology and local inflammatory factors.
Main text
Study design
Forty healthy older adults (aged > 65  years, no chronic 
inflammatory disease, malignancy or immunosuppres-
sive medications) and 37 frail older adults (> 65, frailty 
index > 0.2  [17], able to provide written consent, no 
malignancy or immunosuppressive medications) were 
recruited from the community (100% healthy older 
adults; 48.6% frail older adults) or a “medically stable for 
discharge” inpatient population (51.4% frail older adults). 
Table 1 illustrates the demographics of the cohorts.
All individuals underwent assessment of frailty 
[17] and sarcopenia [2] including an ultrasound to deter-
mine quadriceps muscle thickness bilaterally and identify 
the leg with thickest muscle and therefore most suitable 
for biopsy.
During recruitment it was evident that acquiring a suf-
ficient number of muscle biopsy samples would be chal-
lenging, due to participant factor contra-indications to 
muscle biopsies (discussed in “Participant factors” sec-
tion) in frail older adults, and concerns about how rep-
resentative any frail older adult muscle samples would be 
in comparison to the frail older adult cohort as a whole. 
Therefore, this line of investigation was abandoned 
before any muscle samples were taken in either healthy 
older or frail older adults.
The muscle biopsies were planned to be performed 
in an outpatient setting following a single prior visit for 
safety bloods [platelets and international normalised 
ratio (INR)]. The muscle biopsies were to be taken from 
the vastus lateralis with a percutaneous method using a 
Bergstrom needle [14]. This method was chosen due to 
local expertise and success in community-based healthy 
older adults in an inpatient setting [12, 18].
The data presented illustrate the contra-indications 
to muscle biopsies described as participant factors and 
muscle thickness.
Participant factors
Participant factors resulting in contra-indications to 
muscle biopsy were categorised as: safety of biopsy, 
ability to attend for biopsy, ability to care for wound 
post-biopsy and anticipated high risk for complications. 
Examples for each category are described in Additional 
file 1: Table S1 and are specific to this sample.
Clinical guidelines suggest muscle biopsies are not 
performed on individuals on anti-platelet or anti-coagu-
lation therapy [19]; all other contra-indications are pro-
posed on pragmatic grounds and were considered by two 
experienced geriatricians prior to the individual’s exclu-
sion from the muscle biopsy sub-study. Relative contra-
indications are factors which could be mitigated with 
appropriate resources, such as daily nursing care.
17.5% healthy older adults had a recognised contra-
indication to muscle biopsy. All these participants were 
precluded from undergoing a muscle biopsy due to the 
safety of biopsy, secondary to anti-platelet or anti-coag-
ulant use. The majority of frail older adults had more 
than one contra-indication to muscle biopsy: 32.4% had 
a single contra-indication, 40.5% had two, 13.5% had 
three, 5.4% had four and 2.7% had five contra-indica-
tions. Inability to attend (54.1%), due to death, disen-
gagement with services and loss of capacity, and safety 
of the biopsy (51.3%) were the most frequent contra-
indications. Therefore, only 5.4% of the frail older adults 
did not have a contra-indication to muscle biopsy. Fig-
ure  1 demonstrates both the frequency of each contra-
indication and the number of participants with multiple 
contra-indications illustrating the complexities of the 
individuals.
Although these data relate to muscle biopsies per-
formed using the Bergstrom technique, it is also appli-
cable to other percutaneous muscle biopsy techniques, 
conchotome forceps and microbiopsy needle techniques 
[20, 21]. The contra-indications are the same for all the 
techniques, although it could be argued that the incision 
with the microbiopsy needle technique is smaller and, 
therefore, would reduce the burden of post-biopsy care 
on the individual. Nevertheless, even if this was the case 
only 10.8% of the frail older adult population would have 
no contra-indications to muscle biopsy.
Table 1 Demographic data of recruited participants
Data sets: healthy older adults, n = 40; frail older adults, n = 37. Median ± IQR 
are given. Categorical data are given as percentage of total population with raw 
number in brackets. Categorical data tested with Pearson’s Chi Squared and 
continuous data tested with Mann–Whitney U. All data not normally distributed 
except frail older age and frail older frailty index (FI). Statistical difference 
analysed with independent samples Mann–Whitney U
Healthy older adults Frail older adults Statistics
Gender 67.5% (27) female 54.1% (20) female p = 0.241
32.5% (13) male 45.9% (17) male
Age 71.9 ± 9.0 84.0 ± 15.0 p < 0.000
BMI 23.4 ± 4.0 24.9 ± 7.0 p = 0.782
FI 0.03 ± 0.07 0.41 ± 0.17 p < 0.000
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Fig. 1 Frequency of contra-indications to muscle biopsy in the frail older adults. Each row represents a single frail older individual. Each column 
represents the contra-indication. Coloured block represents that individual having that contra-indication
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Muscle thickness
To obtain an adequate muscle sample total muscle thick-
ness of the vastus lateralis and underlying vastus inter-
medius at the site of sampling should be thicker than the 
sum of the needle point (9.5 mm) and window (8.0 mm); 
the total depth of needle point and window of a Berg-
strom needle is 17.5 mm. Therefore, at a muscle thickness 
greater than 17.5  mm, it is possible to obtain a mus-
cle sample between 25 and 140  mg, which is generally 
adequate for most laboratory-based analyses of muscle 
morphology/biochemistry [19]. At a muscle thickness 
between 9.5 mm and 17.5 mm a muscle sample should be 
obtained, but may take multiple passes, and may not be 
of sufficient size for experiments and will likely contain 
subcutaneous adipose tissue. At a muscle thickness less 
than 9.5 mm, no muscle sample will be obtained. Whilst 
there are no reports in the literature of directly measured 
muscle depths linked to failed Bergstrom needle muscle 
biopsies, there are multiple reports of failed needle biop-
sies in patients with significantly wasted muscle [15, 20, 
22].
Muscle thickness of the rectus femoris and vastus 
intermedius at 50% of the femur length (identical thick-
ness to vastus lateralis and vastus intermedius at maxi-
mum cross-sectional area of vastus intermedius, location 
of muscle biopsy site [23]) was measured bilaterally in 40 
healthy older and 30 frail older adults using ultrasound 
[Acuson Antares Premium Edition (Siemens)]. Patients 
were divided into those with adequate (> 17.5 mm), sub-
optimal (9.5–17.5 mm) or inadequate (< 9.5 mm) muscle 
thickness on either leg.
Analysing the entire sample (including those with a 
contra-indication to muscle biopsy) there was adequate 
muscle thickness in all healthy older males and 59.3% 
of the healthy older females. Figure 2 demonstrates that 
although there was a risk of sub-optimal sized muscle 
biopsy in 40.7% of healthy older females, the muscle sam-
ples obtained from these individuals was likely to be suf-
ficient for analysis because the majority of healthy older 
females had muscle thicknesses closer to 17.5  mm than 
9.5 mm.
In frail older adults only 18.7% of females and 21.4% 
of males had adequate muscle thickness for biopsy sam-
pling. 68.8% of frail older females and 57.1% of frail 
older males had sub-optimal muscle thickness, suggest-
ing multiple passes might be required to obtain an ade-
quate sample, and 12.5% of frail older females and 21.4% 
of frail older males had inadequate muscle thickness. In 
the frail older adults with sub-optimal muscle thickness, 
there was a greater proportion of individuals with mus-
cle thickness between 9.5 mm and 13.5 mm suggesting a 
higher chance of a failed muscle biopsy due to inadequate 
sample size.
Discussion
Previous studies have suggested that muscle biopsy is a 
feasible tool in a frail or sarcopenic older population [9–
11, 13]. To our knowledge this is the first study to demon-
strate the difficulties of performing percutaneous muscle 
biopsies in frail older adults and we describe contra-indi-
cations in the majority of frail older adults in our cohort. 
Potential reasons for these reported differences in find-
ings, include study design and the criteria employed to 
diagnose sarcopenia. Successful studies involving biopsy 
investigations approached hundreds more individuals to 
the study than were eventually recruited, with muscle 
biopsies performed in 6.3% of approached pre-frail or 
frail individuals [13] and 9.7% of approached community-
dwelling men, of whom only 6% had sarcopenia [11]. 
Other successful studies diagnosed sarcopenia without 
assessment of muscle strength or physical performance, 
and it is therefore unclear whether these individuals 
had just low muscle mass or sarcopenia [9, 10]. In addi-
tion, a single study used criteria [appendicular lean mass 
(ALM)/body mass index (BMI)], which over identify sar-
copenia in populations with high BMI, in a sample popu-
lation with a mean BMI of 34.0 [9].
Alternative methods of obtaining muscle samples 
include the microbiopsy needle technique and the con-
chotome forceps. The microbiopsy needle is narrower, 
but to compensate, the window for sample collection is 
longer (19 mm) and, therefore, in this sample population 
only adequate muscle biopsy samples would be obtained 
at first pass in 3.7% of healthy older women, 23.1% of 
healthy older men and none of the frail older adults. The 
conchotome forceps are an alternative to a needle biopsy 
technique, with the advantage of the researcher being 
able to operate at shallower depths of muscle [19]. How-
ever, this is at the expense of increased trauma to the area 
with an incision 5–10  mm in length required to access 
the muscle.
We provide evidence that ultrasound assessment of the 
biopsy site prior to needle insertion should be considered 
in all frail populations and female community-dwelling 
older adults. The data presented in this chapter are con-
trary to current literature, which suggests that muscle 
biopsy is feasible in older adults with frailty and/or sarco-
penia [9–11, 13]. In our cohort, the frail older participant 
who could undertake muscle biopsy was not representa-
tive of the group as a whole, introducing the potential for 
bias [younger male, aged 75 (average age in frail older 
adults 84.0); less frail, FI 0.33 (average FI 0.41)]. The pau-
city of negative results in the published literature means 
that whilst muscle biopsy has been possible on occasion 
in these populations, it is unclear whether the data pre-
sented here are an anomaly or represent a common but 
under-reported research experience. This does suggest 
Page 5 of 6Wilson et al. BMC Res Notes          (2018) 11:830 
that if muscle samples are fundamental to the research 
outcomes then the study should be designed to approach 
a large cohort of frail adults. Further research investi-
gating challenges of muscle biopsy in this population is 
essential and should include data on acceptability of the 
technique.
Study limitations
• Muscle biopsy in frail older adults was not the 
designed primary end-point. Successful muscle 
biopsy studies in frail older adults have approached 
and screened much larger cohorts [11, 13].
• Muscle thickness was not measured at site of biopsy 
but at proxy site reported to be of identical thickness 
[23].
• Willingness to undergo a muscle biopsy was not for-
mally recorded but anecdotally only a small proportion 
of the frail older participants were agreeable. This is 
contrary to previous literature [11, 13].
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Fig. 2 Distribution of muscle thickness in healthy and frail older adults. Distribution of muscle thickness: a healthy older women, b healthy older 
men, c frail older women, d frail older men. X axis is muscle thickness measured in mm. Y axis is frequency of individuals. Left of the red line are 
individuals in whom no muscle would be obtained using a Bergstrom needle biopsy technique. Left of the green line are individuals who are at risk 
of inadequate muscle samples using a Bergstrom needle biopsy technique
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Additional file
Additional file 1. Participant factors, both absolute and relative contra-
indications. Table of participant factors present in the frail older adult 
population that are contra-indications to muscle biopsy. Absolute contra-
indications cannot be ameliorated. Relative contra-indications could be 
ameliorated with appropriate resources.
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